阿帕替尼治疗晚期肺恶性肿瘤疗效观察并文献复习  

Efficacy of Apatinib in treatment of advanced lung cancer

作　　者：沈旦[1] 冯薇[1] 杨雯 黄建安[1] 

机构地区：[1]苏州大学附属第一医院呼吸与危重症医学科,江苏苏州215000

出　　处：《临床肺科杂志》2017年第11期2064-2067,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨阿帕替尼在晚期肺恶性肿瘤中的疗效。方法分析2017年3月至4月在苏州大学附属第一医院呼吸与危重症医学科经病理证实的晚期肺恶性肿瘤患者3例,均至少接受过2种静脉系统化疗而无法控制病情,通过观察肺部病灶的变化评价阿帕替尼疗效,并观察不良反应。结果 3例患者中,男性2例,女性1例,年龄61-74岁。其中小细胞肺癌(small cell lung cancer,SCLC)1例,肺腺癌1例,子宫内膜癌肺转移1例。3例患者中,2例病灶部分缓解(partial response,PR),1例病灶稳定(stable disease,SD)。不良反应主要为口腔溃疡(2/3);食欲下降(2/3);低钠血症(2/3);手足综合症(1/3);低钾血症(1/3);肝功能异常(1/3);白细胞下降(1/3),心包积液(1/3),蛋白尿(1/3)。结论阿帕替尼治疗晚期肺恶性肿瘤效果良好,减量口服可耐受不良反应,但仍需要大样本证实。Objective To investigate the efficacy of Apatinib in treatment of advanced malignant tumors in lung. Methods The clinical features of 3 patients with advanced malignant tumors in lung from March to April 2017 were selected, and all of them received at least two kinds of chemotherapy before and their tumors were still making progress. After treating with Apatinib, their pulmonary CT scans and side effects were observed. Results In these patients, 2 cases were male and 1 case was female. The mean age of the subjects was 68. 3 years old. The pathology patterns were small cell lung cancer, adenocarcinoma and metastatic adenocarcinoma from endometrium. The tumors were partial response in 2 cases and stable disease in 1 case. The main side effects were aphthous ulcer （2/3）, loss of appetite （2/3）, hyponatremia （2/3）, hand-foot syndrome （1/3）, hypokalemia （1/3）, elevated liver enzymes （1/3）, leukocyte decrease （1/3）, pericardial effusion （1/3）, and proteinuria （1/3）. Conclusion Apatinib has good effect in advanced malignant tumors in lung, and the side effects are tolerated by reducing the doses. But all these results still need a large sample to verify.

关 键 词：阿帕替尼 晚期肺恶性肿瘤 疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]